MalariaPhase 4START-IPTNCT02009215
School-Based Treatment With ACT to Reduce Transmission
A Phase 4 study testing Dihydroartemisinin-piperaquine (DP) in people with Malaria, run by London School of Hygiene and Tropical Medicine at 1 site in Uganda.
Trial summary
We propose to evaluate the community-level impact of intermittent preventive treatment (IPT) for malaria in schoolchildren on clinical outcomes and malaria transmission, using a cluster-randomised design in Jinja, Uganda. Read more about this study
- Who is it for?
- Ages 5 years and olderHealthy volunteers can take part
- Conditions the study is for
- Malaria
- What is being tested?
- Dihydroartemisinin-piperaquine (DP)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10,746 participants
- Where
- 1 siteUganda
- Study dates
- Feb 2014to Apr 2015
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Student enrolled in a participating intervention school.
- Willingness of parent/guardian to provide written informed consent.
- Provision of written assent by the student (aged 8 years or above).
Who cannot join
- Age < 5 years
- Known allergy or history of adverse reaction to DP
- Menarche in female students
- Weight < 11 kg
- History of cardiac problems or fainting
- Family history of long QT syndrome
Show all 9Show fewer
- Current use of medications known to prolong the QT interval
- Not able to locate parent or guardian, after at least three attempts including parent/teacher association (PTA) meetings and home visits
- Not able to locate the student at school, after at least three attempts
Trial locations and contacts
1 site in 1 country.
About this study
Official title: 'SCHOOL-BASED TREATMENT WITH ACT TO REDUCE TRANSMISSION' (START-IPT): Evaluation of the Community Impact of Intermittent Preventive Treatment for Malaria in Ugandan Children: a Cluster Randomised Trial
We propose to evaluate the community-level impact of intermittent preventive treatment (IPT) for malaria in schoolchildren on clinical outcomes and malaria transmission, using a cluster-randomised design in Jinja, Uganda. Dihydroartemisinin-piperaquine (DP) will be administered to schoolchildren monthly for up to six rounds of treatment during one school year. Outcomes will be measured using surveys of communities, schoolchildren, and mosquito vectors. Our proposal also includes health service research to evaluate the potential feasibility of taking the programme to scale, which will guide future research and implementation of the intervention, and help shape policies in Uganda and elsewhere in Africa.
Read the detailed description
Study objective: The primary objective of the study is to evaluate the impact of IPT for malaria in schoolchildren using monthly DP, as compared with the current standard of care (no IPT), on community-level indicators of malaria transmission. We will test the hypothesis that malaria transmission, as measured by the prevalence of asexual parasitaemia and the entomological inoculation rate (EIR), will be lower in communities surrounding the intervention schools, than those surrounding the control schools.
Study site: The study will be conducted in Jinja district, Uganda.
Clusters: A cluster will be defined as one primary day school plus the 100 closest households surrounding the school. The clusters will be defined prior to randomisation using digitally enumerated maps. We plan to include approximately 84 clusters in the study, with one school per cluster; half will be randomised to the IPT intervention, and half to control.
Randomisation: Randomisation will be conducted by the trial statistician, who is not directly involved in the field activities. Primary schools will be stratified by type of ownership (public vs private). Restricted randomisation will be employed to ensure balance on type of school and geographical location.
Study population: The intervention will be delivered to children attending participating primary schools that are randomised to the intervention group.
The IPT intervention: IPT with dihydroartemisinin-piperaquine (DP) will be delivered to all schools located in the intervention clusters. Treatment will be administered to participating students monthly, for up to 6 rounds of IPT during one school year, and will not be blinded.
Administration of DP: All enrolled students will receive DP (Duo-cotexcin, Holley Cotec Pharmaceuticals) given once a day for 3 consecutive days. DP will be dosed according to weight-based guidelines. Full-strength DP tablets (40/320mg) will be administered orally by study personnel, and all treatments will be directly observed.
Evaluation procedures: Outcomes will be measured through surveys of communities, schoolchildren, and mosquito vectors. In addition, the safety of IPT with monthly DP, and the potential feasibility of the IPT intervention will also be assessed.
- Community surveys. Cross-sectional surveys of community residents living in households randomly selected from each cluster will be conducted at baseline and at the end of intervention.The community surveys will consist of two components: (1) a household survey questionnaire administered to heads of households, and (2) a clinical survey including laboratory testing of all household residents. The primary outcome of the community surveys will be parasite prevalence as measured by microscopy. In the final community survey, we plan to enroll 105 participants per cluster (8820 total).
- School surveys. Cross-sectional surveys of students randomly selected from each cluster school will be conducted at baseline and at the end of intervention. The primary outcome of the school surveys will be parasite prevalence as measured by microscopy. In the final school survey, we plan to enroll 13 students per cluster (1092 total).
- Entomology surveys. Mosquitos will be collected using Centers of Disease Control and Prevention (CDC) light traps from 5 randomly selected households from 20 clusters in each study arm (100 households per arm, 200 total), using a list randomly generated from the enumeration database. Each house will be sampled once a month for the duration of the study. The primary outcome of the entomology surveys will be EIR.
- Safety monitoring. Students enrolled in the intervention will be evaluated prospectively for serious adverse events. To assess the impact of monthly IPT with DP on risk of cardiotoxicity, a sub-set of participants (n=189) will be selected using convenience sampling (from the intervention arm only) to participate in cardiac monitoring and a pharmacokinetic study.
- Qualitative assessment. A qualitative study will run alongside the main trial, to investigate the potential feasibility for integrating this intervention into routine health services and school systems. We will conduct a historical review of published and unpublished literature on programmes that have integrated health interventions into the education sector; ethnographic observation of intervention activities; and in-depth interviews with key stakeholders, and teachers and health workers.
Analytical plan
- Quantitative surveys: All data will be analysed on the basis of intention-to-treat, that is, community residents and school children taking part in the final surveys will be classified as participating in the intervention or control according to the randomization assignment of the cluster they were surveyed in, regardless of whether they (or their children) received the intervention or not. The primary outcome is prevalence of asexual parasitaemia in the community surveys. Prevalence of asexual parasitaemia in the school surveys and EIR are secondary outcome measures. An individual-level approach to the analysis will be used due to the large number of clusters per arm. For binary outcomes, generalised linear Poisson models with log link function will be used. The effect of the intervention will be quantified by calculation of a prevalence risk ratio. For quantitative outcomes, linear regression models will be used. The effect of the intervention will be quantified by calculation of difference in mean outcome. Rate ratios will be used to describe the effect of the intervention on rates. An estimate of the coefficient of variation, k, will be provided overall and for the community survey for each age group (as defined by the stratified sampling). The probability of selection for the final community survey was related to the sampling frame which was determined by the expected parasite prevalence (which varies by age) in age categories; < 5 years, 5-15 years, > 15 years. Therefore, the age structure of the study population is not representative of the community population as a whole. Because we are looking at the community effect we will use inverse probability weights based on the age population structure of all clusters as recorded by the census survey. In practice, each individual will be assigned one of three weights, generated using the census survey, and based on their age as recorded at the final community survey. Population estimates of prevalence will be obtained using svy commands with the cluster as the primary sampling unit and age-related inverse probability weights. Children selected for the school survey were randomly selected after stratification by class. Households selected for the entomological survey were also randomly selected. No weighting is therefore required for the analysis of either the school or entomological surveys. The effect of the intervention will also be assessed using adjusted analyses. The cluster-specific prevalence or mean from the baseline survey will be adjusted for where available. Variables collected in the baseline community survey, which were imbalanced between trial arms, and likely to be prognostic for outcomes will be adjusted for. Secondary analyses will be conducted to assess whether the effect of the intervention differs by age group or school type. The effect of the intervention for each outcome will be examined by age group or school type and tests for interaction conducted.
- Qualitative data: The data analysis of the field notes and in-depth interviews will follow a bottom-up approach, identifying repeating patterns in the data. Field notes will be coded on a daily basis using qualitative data analysis software, NVivo (QSR International, Cambridge, MA). Transcripts will be coded line-by-line, and then later developing themes and theoretical constructs by grouping the base coding together. A coding template will be developed and refined. Following the coding process, themes and theoretical constructs will be developed from both the field notes and the interview transcripts, and the analysis will be conducted with reference to the literature and theory regarding school-based and cross-sectoral interventions. Following this analysis, the interpretation will take on an applied stance, to seek out specific challenges and opportunities for methods and content of interventions to support implementation of IPT.
- Conditions
- Malaria
- Being tested
- Dihydroartemisinin-piperaquine (DP)
- Keywords
- Uganda, intermittent preventive treatment, dihydroartemisinin-piperaquine, schoolchildren, malaria
- Medical subject headings
- Malaria
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dihydroartemisinin-piperaquine (DP)Drug
Also called Duo-cotecxin
Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
| Study group | Role | What they receive |
|---|---|---|
| Intermittent preventive treatment (IPT) | Experimental | Dihydroartemisinin-piperaquine (DP) Receives: Drug: Dihydroartemisinin-piperaquine (DP) |
| Control | No intervention | No intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be given. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Parasite prevalence measured by microscopy in final community survey
Proportion of thick blood smears that are positive for asexual parasites, as measured by microscopy.
Measured: Approximately 1-4 months after completion of the intervention
Secondary outcomes (2)
Entomologic inoculation rate (EIR) in the entomology survey
EIR will be defined as the number of infectious bites per person per year (the human biting rate multiplied by the sporozoite rate).
Measured: Over approximately 1 year
Parasite prevalence measured by microscopy in the final school survey
Proportion of thick blood smears that are positive for asexual parasites, as measured by microscopy.
Measured: During the final 1 month of the intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2013 (estimated)
- Study startFeb 2014
- Primary completionApr 2015
- Study completionApr 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for MalariaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 10,746 participants (actual)
Sponsor and investigators
- Lead sponsor
- London School of Hygiene and Tropical Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- Infectious Diseases Research Collaboration, Uganda, University of California, San Francisco, University of Durham
- Responsible party
- Principal investigator, Sarah Staedke, London School of Hygiene and Tropical Medicine
- Investigators
- Sarah G Staedke, MD, PhD, Principal investigator, London School of Hygiene and Tropical Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02009215
- Sponsor's protocol ID
- ITCRAA6910
- Acronym
- START-IPT
- Status last verified
- Sep 2015
- First submitted
- 23 Oct 2013
- Last updated
- 24 Sep 2015
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Nankabirwa J, Cundill B, Clarke S, Kabatereine N, Rosenthal PJ, Dorsey G, Brooker S, Staedke SG. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS One. 2010 Oct 19;5(10):e13438. doi: 10.1371/journal.pone.0013438.
PubMed 20976051Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, Brooker SJ, Staedke SG, Kamya MR. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis. 2014 May;58(10):1404-12. doi: 10.1093/cid/ciu150. Epub 2014 Mar 12.
PubMed 24621953Rehman AM, Maiteki-Sebuguzi C, Gonahasa S, Okiring J, Kigozi SP, Chandler CIR, Drakeley C, Dorsey G, Kamya MR, Staedke SG. Intermittent preventive treatment of malaria delivered to primary schoolchildren provided effective individual protection in Jinja, Uganda: secondary outcomes of a cluster-randomized trial (START-IPT). Malar J. 2019 Sep 18;18(1):318. doi: 10.1186/s12936-019-2954-0.
PubMed 31533845Staedke SG, Maiteki-Sebuguzi C, Rehman AM, Kigozi SP, Gonahasa S, Okiring J, Lindsay SW, Kamya MR, Chandler CIR, Dorsey G, Drakeley C. Assessment of community-level effects of intermittent preventive treatment for malaria in schoolchildren in Jinja, Uganda (START-IPT trial): a cluster-randomised trial. Lancet Glob Health. 2018 Jun;6(6):e668-e679. doi: 10.1016/S2214-109X(18)30126-8. Epub 2018 Apr 13.
PubMed 29661635
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 'SCHOOL-BASED TREATMENT WITH ACT TO REDUCE TRANSMISSION' (START-IPT): Evaluation of the Community Impact of Intermittent Preventive Treatment for Malaria in Ugandan Children: a Cluster Randomised Trial
- ClinicalTrials.gov ID
- NCT02009215
- Acronym / sponsor ID
- START-IPT / ITCRAA6910
- Conditions
- Malaria
- Keywords
- Uganda, intermittent preventive treatment, dihydroartemisinin-piperaquine, schoolchildren, malaria
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10,746 participants (actual)
- Lead sponsor
- London School of Hygiene and Tropical MedicineUniversity, hospital or other
- Collaborators
- Infectious Diseases Research Collaboration, Uganda, University of California, San Francisco, University of Durham
- Study start
- Feb 2014
- Primary completion
- Apr 2015 (actual)
- Study completion
- Apr 2015 (actual)
- First posted
- 11 Dec 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We propose to evaluate the community-level impact of intermittent preventive treatment (IPT) for malaria in schoolchildren on clinical outcomes and malaria transmission, using a cluster-randomised design in Jinja, Uganda. Dihydroartemisinin-piperaquine (DP) will be administered to schoolchildren monthly for up to six rounds of treatment during one school year. Outcomes will be measured using surveys of communities, schoolchildren, and mosquito vectors. Our proposal also includes health service research to evaluate the potential feasibility of taking the programme to scale, which will guide future research and implementation of the intervention, and help shape policies in Uganda and elsewhere in Africa.
Detailed description
Study objective: The primary objective of the study is to evaluate the impact of IPT for malaria in schoolchildren using monthly DP, as compared with the current standard of care (no IPT), on community-level indicators of malaria transmission. We will test the hypothesis that malaria transmission, as measured by the prevalence of asexual parasitaemia and the entomological inoculation rate (EIR), will be lower in communities surrounding the intervention schools, than those surrounding the control schools.
Study site: The study will be conducted in Jinja district, Uganda.
Clusters: A cluster will be defined as one primary day school plus the 100 closest households surrounding the school. The clusters will be defined prior to randomisation using digitally enumerated maps. We plan to include approximately 84 clusters in the study, with one school per cluster; half will be randomised to the IPT intervention, and half to control.
Randomisation: Randomisation will be conducted by the trial statistician, who is not directly involved in the field activities. Primary schools will be stratified by type of ownership (public vs private). Restricted randomisation will be employed to ensure balance on type of school and geographical location.
Study population: The intervention will be delivered to children attending participating primary schools that are randomised to the intervention group.
The IPT intervention: IPT with dihydroartemisinin-piperaquine (DP) will be delivered to all schools located in the intervention clusters. Treatment will be administered to participating students monthly, for up to 6 rounds of IPT during one school year, and will not be blinded.
Administration of DP: All enrolled students will receive DP (Duo-cotexcin, Holley Cotec Pharmaceuticals) given once a day for 3 consecutive days. DP will be dosed according to weight-based guidelines. Full-strength DP tablets (40/320mg) will be administered orally by study personnel, and all treatments will be directly observed.
Evaluation procedures: Outcomes will be measured through surveys of communities, schoolchildren, and mosquito vectors. In addition, the safety of IPT with monthly DP, and the potential feasibility of the IPT intervention will also be assessed.
- Community surveys. Cross-sectional surveys of community residents living in households randomly selected from each cluster will be conducted at baseline and at the end of intervention.The community surveys will consist of two components: (1) a household survey questionnaire administered to heads of households, and (2) a clinical survey including laboratory testing of all household residents. The primary outcome of the community surveys will be parasite prevalence as measured by microscopy. In the final community survey, we plan to enroll 105 participants per cluster (8820 total).
- School surveys. Cross-sectional surveys of students randomly selected from each cluster school will be conducted at baseline and at the end of intervention. The primary outcome of the school surveys will be parasite prevalence as measured by microscopy. In the final school survey, we plan to enroll 13 students per cluster (1092 total).
- Entomology surveys. Mosquitos will be collected using Centers of Disease Control and Prevention (CDC) light traps from 5 randomly selected households from 20 clusters in each study arm (100 households per arm, 200 total), using a list randomly generated from the enumeration database. Each house will be sampled once a month for the duration of the study. The primary outcome of the entomology surveys will be EIR.
- Safety monitoring. Students enrolled in the intervention will be evaluated prospectively for serious adverse events. To assess the impact of monthly IPT with DP on risk of cardiotoxicity, a sub-set of participants (n=189) will be selected using convenience sampling (from the intervention arm only) to participate in cardiac monitoring and a pharmacokinetic study.
- Qualitative assessment. A qualitative study will run alongside the main trial, to investigate the potential feasibility for integrating this intervention into routine health services and school systems. We will conduct a historical review of published and unpublished literature on programmes that have integrated health interventions into the education sector; ethnographic observation of intervention activities; and in-depth interviews with key stakeholders, and teachers and health workers.
Analytical plan
- Quantitative surveys: All data will be analysed on the basis of intention-to-treat, that is, community residents and school children taking part in the final surveys will be classified as participating in the intervention or control according to the randomization assignment of the cluster they were surveyed in, regardless of whether they (or their children) received the intervention or not. The primary outcome is prevalence of asexual parasitaemia in the community surveys. Prevalence of asexual parasitaemia in the school surveys and EIR are secondary outcome measures. An individual-level approach to the analysis will be used due to the large number of clusters per arm. For binary outcomes, generalised linear Poisson models with log link function will be used. The effect of the intervention will be quantified by calculation of a prevalence risk ratio. For quantitative outcomes, linear regression models will be used. The effect of the intervention will be quantified by calculation of difference in mean outcome. Rate ratios will be used to describe the effect of the intervention on rates. An estimate of the coefficient of variation, k, will be provided overall and for the community survey for each age group (as defined by the stratified sampling). The probability of selection for the final community survey was related to the sampling frame which was determined by the expected parasite prevalence (which varies by age) in age categories; < 5 years, 5-15 years, > 15 years. Therefore, the age structure of the study population is not representative of the community population as a whole. Because we are looking at the community effect we will use inverse probability weights based on the age population structure of all clusters as recorded by the census survey. In practice, each individual will be assigned one of three weights, generated using the census survey, and based on their age as recorded at the final community survey. Population estimates of prevalence will be obtained using svy commands with the cluster as the primary sampling unit and age-related inverse probability weights. Children selected for the school survey were randomly selected after stratification by class. Households selected for the entomological survey were also randomly selected. No weighting is therefore required for the analysis of either the school or entomological surveys. The effect of the intervention will also be assessed using adjusted analyses. The cluster-specific prevalence or mean from the baseline survey will be adjusted for where available. Variables collected in the baseline community survey, which were imbalanced between trial arms, and likely to be prognostic for outcomes will be adjusted for. Secondary analyses will be conducted to assess whether the effect of the intervention differs by age group or school type. The effect of the intervention for each outcome will be examined by age group or school type and tests for interaction conducted.
- Qualitative data: The data analysis of the field notes and in-depth interviews will follow a bottom-up approach, identifying repeating patterns in the data. Field notes will be coded on a daily basis using qualitative data analysis software, NVivo (QSR International, Cambridge, MA). Transcripts will be coded line-by-line, and then later developing themes and theoretical constructs by grouping the base coding together. A coding template will be developed and refined. Following the coding process, themes and theoretical constructs will be developed from both the field notes and the interview transcripts, and the analysis will be conducted with reference to the literature and theory regarding school-based and cross-sectoral interventions. Following this analysis, the interpretation will take on an applied stance, to seek out specific challenges and opportunities for methods and content of interventions to support implementation of IPT.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intermittent preventive treatment (IPT) | Experimental | Drug: Dihydroartemisinin-piperaquine (DP)Dihydroartemisinin-piperaquine (DP) |
| Control | No intervention | –No intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be given. |
Who may qualify
- Ages
- 5 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Student enrolled in a participating intervention school.
- Willingness of parent/guardian to provide written informed consent.
- Provision of written assent by the student (aged 8 years or above).
Key exclusion criteria (9 listed)
- Age < 5 years
- Known allergy or history of adverse reaction to DP
- Menarche in female students
- Weight < 11 kg
- History of cardiac problems or fainting
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dihydroartemisinin-piperaquine (DP)Also: Duo-cotecxinIntermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded. | Drug | Intermittent preventive treatment (IPT) |
Primary outcome
Parasite prevalence measured by microscopy in final community survey
Time frame: Approximately 1-4 months after completion of the intervention
Proportion of thick blood smears that are positive for asexual parasites, as measured by microscopy.
2 secondary outcomes
Entomologic inoculation rate (EIR) in the entomology survey
Time frame: Over approximately 1 year
Parasite prevalence measured by microscopy in the final school survey
Time frame: During the final 1 month of the intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2015.
- Background: PubMed 20976051Nankabirwa J, Cundill B, Clarke S, Kabatereine N, Rosenthal PJ, Dorsey G, Brooker S, Staedke SG. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS One. 2010 Oct 19;5(10):e13438. doi: 10.1371/journal.pone.0013438.
- Background: PubMed 24621953Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, Brooker SJ, Staedke SG, Kamya MR. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis. 2014 May;58(10):1404-12. doi: 10.1093/cid/ciu150. Epub 2014 Mar 12.
- Derived from this study: PubMed 31533845Rehman AM, Maiteki-Sebuguzi C, Gonahasa S, Okiring J, Kigozi SP, Chandler CIR, Drakeley C, Dorsey G, Kamya MR, Staedke SG. Intermittent preventive treatment of malaria delivered to primary schoolchildren provided effective individual protection in Jinja, Uganda: secondary outcomes of a cluster-randomized trial (START-IPT). Malar J. 2019 Sep 18;18(1):318. doi: 10.1186/s12936-019-2954-0.
- Derived from this study: PubMed 29661635Staedke SG, Maiteki-Sebuguzi C, Rehman AM, Kigozi SP, Gonahasa S, Okiring J, Lindsay SW, Kamya MR, Chandler CIR, Dorsey G, Drakeley C. Assessment of community-level effects of intermittent preventive treatment for malaria in schoolchildren in Jinja, Uganda (START-IPT trial): a cluster-randomised trial. Lancet Glob Health. 2018 Jun;6(6):e668-e679. doi: 10.1016/S2214-109X(18)30126-8. Epub 2018 Apr 13.
- Infectious Disease Research Collaboration (IDRC), Uganda Malaria Surveillance Project (UMSP), Makerere University - University of California, San Francisco (MU-UCSF)Link provided by the sponsor.
Related trials for Malaria
Active, not recruitingPhase 4
Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics
Malaria,Falciparum, Malaria in Pregnancy
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
Not yet recruiting
Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee Settings
Malaria (Plasmodium Falciparum), Malaria Incidence
Not yet recruitingObservational study
Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda
Malaria
RecruitingObservational study
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
Malaria
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sarah G Staedke, MD, PhD principal investigator
London School of Hygiene and Tropical Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Dihydroartemisinin-piperaquine (DP) in people with Malaria, run by London School of Hygiene and Tropical Medicine at 1 site in Uganda.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Parasite prevalence measured by microscopy in final community survey (time frame: Approximately 1-4 months after completion of the intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02009215, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2015; AzTrials last refreshed its copy on 31 Oct 2026.